Back to search

Peptide record

TPDB41200

EEK Anticancer standard
15 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB41200
EEK
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 15-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
C-terminal: Amidation
Sequence
GLLELLELLLKAAGW-NH2
Physicochemical Analysis
C79H131N17O20
RNDCQHIMFPSTYV
L
1639.01
4.26
1
2
10
-1
-1.06
1.173
195.33
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
5500
335.57
0
Residue Composition
number
2
A
0
R
0
N
0
D
0
C
2
E
0
Q
2
G
0
H
0
I
7
L
1
K
0
M
0
F
0
P
0
S
0
T
1
W
0
Y
0
V
Amino Acid Distribution
A: 2 R: 0 N: 0 D: 0 C: 0 E: 2 Q: 0 G: 2 H: 0 I: 0 L: 7 K: 1 M: 0 F: 0 P: 0 S: 0 T: 0 W: 1 Y: 0 V: 0
Chemical Descriptors
15
C79H131N17O20
1639.01
4.26
-1
-1.06
1.173
Amidation
L
Linear
Free
Anticancer
Synthetic
Evidence Records 3 records
Evidence 1 Activity

Activity

IC50
IC50 = 1.10 ± 0.14 µM
Anticancer
1.10

Target

Breast Cancer
HMLER
Breast

Assay & Model

MTT assay
72-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 1.08 ± 0.18 µM
Anticancer
1.08

Target

Breast Cancer
HMLER-shEcad
Breast

Assay & Model

MTT assay
72-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022
Evidence 3 Activity

Activity

IC50
IC50 = 32.88 ± 4.07 µM
Anticancer
32.88

Target

Bone Cancer
U-2 OS
Bone

Assay & Model

MTT assay
72-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022